TTFB  (Synonyms: N-(4-tert-butyl-1,3-thiazol-2-yl)-3-fluorobenzamide)

TTFB (N-(4-tert-butyl-1,3-thiazol-2-yl)-3-fluorobenzamide) is a selective, non-competitive zinc-activated channel (ZAC) antagonist. TTFB inhibits Zn²⁺- and H⁺-induced ZAC currents with IC₅₀ values of 3 μM and 8.5 μM, respectively, and has an IC₅₀ of 4.7 μM against spontaneous activity. TTFB shows no significant agonistic, antagonistic or modulatory activity towards representative classical Cys-loop receptors including m5-HT3AR, hα3β4 nAChR, hα1β2γ2S GABAAR and hα1 GlyR. TTFB can be used to investigate the physiological and pathological functions of ZAC.

TTFB (0.1-100 μM; 30 seconds) potently inhibits Zn²⁺-evoked, H⁺-evoked, and spontaneous ZAC activity in Xenopus oocytes with IC₅₀ values of 3.0 μM, 8.5 μM, and 4.7 μM, respectively, and mediates complete inhibition of Zn²⁺-induced responses^[1].
TTFB (10 μM) mediates ZAC inhibition that is voltage-independent, as it inhibits H⁺-evoked currents similarly at -60 mV and +60 mV^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

278.35

C₁₄H₁₅FN₂OS

352560-76-0

Solid

O=C(NC1=NC(=CS1)C(C)(C)C)C=2C=CC=C(F)C2

Room temperature in continental US; may vary elsewhere.

• [1]. Madjroh N, et al. Discovery and functional characterization of N-(thiazol-2-yl)-benzamide analogs as the first class of selective antagonists of the Zinc-Activated Channel (ZAC). Biochem Pharmacol. 2021;193:114782.  [Content Brief]